Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
NCT02789657
Completed
Neoadjuvant therapy is given to breast cancer patients whose cancers are relatively large or have spread to lymph nodes or both. The primary goal of this treatment is to prevent the cancer from coming back (recurring) elsewhere in the body, but if it makes the cancer in the breast and lymph nodes shrink it might be easier to remove. This could allow a patient to have a lumpectomy instead of a mastectomy and reduce the number of lymph nodes that the surgeon has to remove. In some cases, the neoad... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/27/2022
Locations: Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island +1 locations
Conditions: Breast Cancer
Register for Updates
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
NCT00432094
Completed
RATIONALE: Germ cell tumors (GCT) are highly sensitive to chemotherapy such that even with metastatic disease at diagnosis, many patients can be cured. Patients who fall into the poor risk category or others who relapse can be successfully salvaged with high dose chemotherapy and autologous stem cell transplant (AuSCT). As in other diseases such as myeloma, sequential high dose chemotherapy and AuSCT may improve overall and disease free survival. PURPOSE: Because prior investigations in GCT sug... Read More
Gender:
ALL
Ages:
Between 10 years and 69 years
Trial Updated:
04/22/2022
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota
Conditions: Childhood Germ Cell Tumor, Ovarian Cancer, Teratoma
Register for Updates
LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer
NCT04762901
Withdrawn
This is an open-label, two-stage, multi-arm Phase 1 study designed to evaluate the safety and preliminary efficacy of combining niraparib with four standard chemotherapy regimens used to treat TNBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2022
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Breast Cancer
Register for Updates
Carboplatin and Bevacizumab for Recurrent Ependymoma
NCT01295944
Completed
The goal of this clinical research study is to learn if the combination of bevacizumab and carboplatin can help to control recurrent ependymoma. The safety of this drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2022
Locations: Massachusetts General Hospital/Dana Farber, Boston, Massachusetts +1 locations
Conditions: Ependymoma, Anaplastic Ependymoma
Register for Updates
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
NCT02471911
Completed
This study evaluates the addition of selinexor (KPT-330) to RICE chemotherapy in the treatment of relapsed and refractory aggressive B-Cell Lymphoma, with the goal of improved response rates (as compared to RICE chemotherapy alone).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2022
Locations: Weill Cornell Medical College, New York, New York
Conditions: Diffuse Large B-Cell Lymphoma
Register for Updates
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
NCT03041311
Terminated
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing antitumor efficacy when administered with carboplatin, etoposide, and atezolizumab (E/P/A) therapy in first line treatment for patients with newly diagnosed extensive-stage SCLC. The study was a randomized, double-blinded, placebo-controlled design. Approximately, 100 patients were randomized to trilaciclib + E/P/A or placebo + E/P/A in the stu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2022
Locations: Beverly Hills Cancer Center, Beverly Hills, California +44 locations
Conditions: Small Cell Lung Cancer
Register for Updates
First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC
NCT00456261
Completed
This trial will look at 2 different drug combinations that have well known safety profiles and are known to be active against non small cell lung cancer and combine them with bevacizumab, an experimental drug that has shown effectiveness when added to other drug combinations for advanced non-small cell lung cancer. The primary objective in this study is to see how well this combination of drugs keeps the cancer from getting worse in this elderly population of non-small cell lung cancer patients.
Gender:
ALL
Ages:
70 years and above
Trial Updated:
04/08/2022
Locations: Northeast Alabama Regional Medical Center, Anniston, Alabama +17 locations
Conditions: Lung Cancer
Register for Updates
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
NCT00567567
Completed
This randomized phase III trial compares two different high-dose chemotherapy regimens followed by a stem cell transplant in treating younger patients with high-risk neuroblastoma. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments before a... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/01/2022
Locations: Children's Hospital of Alabama, Birmingham, Alabama +189 locations
Conditions: Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Register for Updates
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
NCT01721746
Completed
The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/23/2022
Locations: Mayo Clinic, Phoenix, Arizona +94 locations
Conditions: Unresectable or Metastatic Melanoma
Register for Updates
Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC
NCT03838367
Unknown
This is a phase Ib/II Study of Leronlimab (PRO 140) combined with Carboplatin in Patients with CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC). Study population will consist of patients with CCR5-positive, locally advanced or metastatic triple-negative breast cancer (mTNBC) who are naïve to chemotherapy in metastatic setting but have been exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings (first-line).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/18/2022
Locations: Quest Clinical Research, San Francisco, California +1 locations
Conditions: Triple Negative Breast Neoplasms
Register for Updates
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
NCT02367794
Completed
This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2022
Locations: Ironwood Cancer & Research Centers, Chandler, Arizona +241 locations
Conditions: Squamous Non-Small Cell Lung Cancer
Register for Updates
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
NCT00303849
Completed
This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, etoposide phosphate, mannitol, and sodium thiosulfate and to see how well they work in treating patients with previously treated brain tumors. Drugs used in chemotherapy, such as melphalan, carboplatin, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Osm... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/11/2022
Locations: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota +1 locations
Conditions: Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma, Oligoastrocytoma
Register for Updates